The SBF was established in 2009 with initial financial support from the Scottish Universities Life Sciences Alliance (SULSA) and the University of Aberdeen. The facility capitalises on its access to the SULSA community, and in turn, to specific targets identified by SULSA members' research teams. SBF has its strong foundation on University of Aberdeen's internationally recognised antibody engineering research group which has a long and distinguished track record of success generating antibodies that have been commercialised in diagnostic kits or developed as therapeutic leads.
Within a few years of its formation, SBF have managed to generate considerable levels of interest amongst researchers wishing to collaborate with the facility. Through a series of different academic groupings and training of PhD students, the SBF has been able to initiate a number of early therapeutic programmes in a wide variety of clinical areas including: infectious disease (anti-fungal and anti-bacterial), oncology, cardiovascular diseases and CNS.
The facility is located at the Liberty Building which is part of University of Aberdeen's Foresterhill site. The facility is offering antibody selection to academic partners as part of SULSA's Translational Biology Screening.